Rice Hall James & Associates LLC Takes Position in Xeris Biopharma Holdings, Inc. $XERS
Rice Hall James & Associates LLC has acquired a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), purchasing 300,791 shares valued at approximately $2.38 million in the second quarter. The article details other institutional investors' activities, Xeris Biopharma's financial performance, and recent insider trading. Despite mixed analyst ratings, the stock has shown upward movement, but the company missed EPS estimates in its latest quarterly report.
Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses
Xeris Biopharma (XERS) shares rose 6.6% despite reporting wider net losses in Q2 2026, as the company tightened its full-year 2026 revenue guidance to US$385 million–US$390 million. The company's investment narrative highlights strong revenue growth potential driven by its endocrine and diabetes portfolio, but rising costs and widening losses remain a key risk. Analysts have varying forecasts, with some predicting a significant upside to the current stock price if cost pressures ease.
Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses
Xeris Biopharma Holdings (XERS) saw its stock rise 6.6% despite reporting wider net losses in Q2 2026 and for the first half of 2026. The company tightened its full-year 2026 revenue guidance to US$385 million–US$390 million, offering clearer expectations. This update, alongside recent board changes, emphasizes the ongoing challenge of rising costs outpacing revenue growth for the biopharma company.
Xeris Biopharma Holdings (XERS) Could Be 23% Undervalued As Guidance Tightens And Pipeline Progress Continues
Xeris Biopharma Holdings (XERS) is gaining attention after tighter full-year revenue guidance and second-quarter results were released on August 6, 2026. The stock is considered 22.8% undervalued with a fair value of $11.14 per share, compared to its current price of $8.60. This valuation is supported by projected faster top-line growth, higher profit margins, and the anticipated launch of XP-8121 for hypothyroidism, despite widening losses being a concern for some.
Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS
Walleye Capital LLC has invested $4.84 million in Xeris Biopharma Holdings, Inc. by acquiring 611,296 shares in the second quarter, representing 0.35% of the company. Institutional investors collectively own 42.75% of Xeris. Despite reporting higher-than-expected revenue of $92.1 million, the company posted an adjusted loss of $0.18 per share, missing analyst estimates.
Mission Produce And Two Other Stocks Estimated To Be Trading Below Intrinsic Value
The article highlights three US stocks—Mission Produce (AVO), Xeris Biopharma Holdings (XERS), and Gold Royalty (GROY)—that are estimated to be trading below their intrinsic value based on future cash flow. Despite recent financial challenges for some, all three companies show strong projected earnings growth. Investors are encouraged to explore these undervalued opportunities.
XERS|Xeris Biopharma Holdings Inc|Price:8.322|Chg%:-0.168
This page provides an overview of Xeris Biopharma Holdings Inc (XERS), including its live stock price, key financial figures, technical analysis, and analyst ratings. The company, which specializes in developing and commercializing products for various therapies like Cushing's syndrome and severe hypoglycemia, currently holds a "Buy" rating from analysts with a target price of $11.286. Key metrics such as market cap, P/E ratio, and recent stock performance are detailed, alongside information on its product pipeline and major shareholders.
Mission Produce And Two Other Stocks Estimated To Be Trading Below Intrinsic Value
This article identifies Mission Produce, Xeris Biopharma Holdings, and Gold Royalty as three U.S. stocks currently trading below their estimated intrinsic value based on future cash flows. It provides an overview of each company's operations, estimated discount to fair value, and growth prospects, including forecasted earnings growth and recent financial performance. The analysis aims to help investors find potential opportunities for appreciation in a rising market.
Xeris Biopharma (XERS) insider Steven Pieper plans Rule 144 sale of 20,000 shares
Xeris Biopharma insider Steven Pieper has filed to sell 20,000 common shares under Rule 144, with an aggregate market value of $167,800.00, to be handled by Morgan Stanley Smith Barney LLC. These shares originated from Restricted Stock Units granted in January 2025. This planned sale follows previous 10b5-1 plan sales by Pieper in July 2026, totaling 45,000 shares for over $380,000.
Renaissance Technologies LLC Cuts Stock Position in Xeris Biopharma Holdings, Inc. $XERS
Renaissance Technologies LLC reduced its stake in Xeris Biopharma Holdings, Inc. by 26.9% in the first quarter, selling 166,800 shares but still owning 452,860 shares valued at approximately $2.63 million. Institutional investors collectively hold 42.75% of XERS, and analysts maintain a "Moderate Buy" consensus with an average price target of $10.80. Despite exceeding revenue estimates, Xeris reported an EPS loss of $0.18, and company insiders sold 266,499 shares worth about $2.0 million over the past three months.
Xeris Biopharma Holdings Inc (XERS) Stock News Today
This article provides current stock information for Xeris Biopharma Holdings Inc (XERS) including its recent closing price, market capitalization, and P/E ratio. It highlights that the company's stock experienced a gain of 7.74% and indicates that more news and earnings updates are expected soon for XERS.
Should Xeris Biopharma Holdings (XERS) Be Revalued After Strong Q2 Revenue And Fresh Guidance?
Xeris Biopharma Holdings (XERS) is attracting investor attention following its Q2 earnings report, which included strong performance and a refined full-year 2026 revenue outlook. The stock is currently trading at $7.93, with a recent 7.74% one-day return, and analysts consider it undervalued with a fair value estimated at $11.14. This valuation hinges on anticipated revenue growth from new product launches and margin expansion, despite concerns about rising R&D and SG&A expenses.
Xeris Biopharma Holdings, Inc. 2026: Revenue $92.1M, EPS ($0.18) — 10-Q Summary
Xeris Biopharma Holdings, Inc. reported its 2026 quarterly results with revenue reaching $92.1 million, an increase of 28.7% year-over-year. Despite the revenue growth, the company recorded a net loss of ($31.1M) and a diluted EPS of ($0.18), driven by higher product sales and increased operating investments. The growth was primarily fueled by an 80.6% surge in Recorlev sales and progress in its R&D pipeline for XP-8121.
Xeris Biopharma Holdings, Inc. reports results for the quarter ended June 30 - Earnings Summary
Xeris Biopharma Holdings, Inc. has released its earnings summary for the quarter that concluded on June 30. The report is provided by Refinitiv and is available to TradingView users with unlimited access to news articles.
Earnings call transcript: Xeris Biopharma posts Q2 2026 revenue beat, EPS miss
Xeris Biopharma reported a Q2 2026 revenue beat of $92.1 million, surpassing Wall Street estimates, but missed EPS expectations with a loss of $0.18 per share. The company attributed the EPS miss primarily to a one-time non-cash GAAP charge related to convertible note remeasurement. Despite the earnings miss, Xeris raised its full-year 2026 revenue guidance to $385 million-$390 million, driven by strong commercial momentum, particularly from RECORLEV, and the expected initiation of Phase III testing for XP-8121 by year-end.
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics
Xeris Biopharma (XERS) reported Q2 2026 revenue of $92.1 million, a 28.7% year-over-year increase, surpassing the Zacks Consensus Estimate. However, the EPS of $0 missed the consensus estimate of $0.02. Key product revenues varied, with Recorlev showing significant growth while Gvoke and Keveyis experienced declines.
(XERS) Xeris Biopharma Expects Full Year 2026 Revenue Range $385M - $390M, vs. FactSet Est of $385.9M
Xeris Biopharma Holdings, Inc. announced its full-year 2026 revenue guidance, projecting a range of $385 million to $390 million. This forecast is in line with FactSet's estimated revenue of $385.9 million. The company also provided an update on its second-quarter earnings for 2026.
Xeris Biopharma (NASDAQ:XERS) Insider Kevin Mcculloch Sells 15,000 Shares of Stock
Kevin Mcculloch, an insider at Xeris Biopharma (NASDAQ:XERS), sold 15,000 shares of the company's stock for $120,300 on August 3rd, reducing his total holdings by 0.89%. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. The company's stock has shown positive performance, trading up at $8.19 with a market capitalization of $1.41 billion, and analysts maintain a "Moderate Buy" rating with an average price target of $10.80.
Xeris Biopharma (XERS) Insider Beth Hecht Sells 16,666 Shares
Xeris Biopharma insider Beth Hecht sold 16,666 shares of XERS for $8.01 per share on August 3, 2026, totaling approximately $133,495. This
Xeris Biopharma President, COO Kevin McCulloch sells 15,000 shares for $120,240
Xeris Biopharma President and COO Kevin McCulloch sold 15,000 common shares for $120,240 on August 3, 2026, at a price of $8.02 per share. Following this transaction, his direct stake increased to 1,676,126 shares. The report also noted his spouse indirectly holds 25,000 shares.
Vanguard Capital Management (XERS) discloses 8.64M-share, 5% holding in Xeris
Vanguard Capital Management LLC and its affiliates have reported a 5% beneficial ownership stake in Xeris Biopharma Holdings Inc, amounting to 8,637,640 common shares. This disclosure, made via a Schedule 13G filing, indicates that Vanguard holds sole voting power over 1,297,411 shares and sole dispositive power over all 8,637,640 shares. The filing confirms that no single person other than Vanguard has an interest exceeding 5% in the reported securities, which are held across various Vanguard funds and managed accounts.
XERS|Xeris Biopharma Holdings Inc|Price:8.415|Chg%:+0.035
This article provides a detailed financial overview of Xeris Biopharma Holdings Inc (XERS), including its stock price, market cap, P/E ratio, and upcoming earnings date. It presents comprehensive financial statements like the income statement, balance sheet, and cash flow statement, broken down quarterly and annually. The data highlights key financial indicators such as EPS, revenue, net profit, net margin, gross margin, and debt-to-assets ratio, along with FAQs summarizing recent fiscal year performance details.
Xeris Biopharma (XERS) Expected to Release Quarterly Earnings on Thursday
Xeris Biopharma (XERS) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 6th. Analysts project earnings of $0.02 per share and approximately $90.1 million in revenue. The company currently holds a "Moderate Buy" consensus rating with an average price target of $10.80, although insiders have been net sellers of the stock recently.
Xeris Biopharma Holdings Inc (XERS) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Xeris Biopharma Holdings Inc (XERS), noting its current valuation score of 8.01 within the Pharmaceuticals industry. It highlights the company's P/E ratio of 104.89, which is significantly below its recent high but above its recent low. Key valuation metrics like P/B, P/S, and P/CF are reported as not yet disclosed.
Xeris Biopharma Holdings Inc (XERS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Xeris Biopharma Holdings Inc (XERS), detailing its current price momentum, support and resistance levels, and various technical indicators. The stock's price momentum score is 3.43, and it is trading between a resistance level of $8.98 and a support level of $7.81. The analysis also includes a summary of buy, sell, and neutral signals from indicators like MACD, RSI, and moving averages, concluding with an overall neutral signal based on moving averages and other technical indicators.
Xeris Biopharma Holdings Inc (XERS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Xeris Biopharma Holdings Inc (XERS) has an earnings forecast score of 8.57, ranking 26th in the Pharmaceuticals industry. Analysts have an average price target of $10.00 for XERS, with a consensus "Buy" rating based on 7 analysts. The expected revenue for the next quarter is $90.22 million.
Rice Hall James & Associates LLC Acquires Shares of 251,066 Xeris Biopharma Holdings, Inc. $XERS
Rice Hall James & Associates LLC recently acquired 251,066 shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) worth approximately $1.46 million, contributing to institutional and hedge fund ownership of 42.75% of the company. Analysts maintain a "Moderate Buy" rating with a consensus target price of $10.80, despite recent insider share sales totaling about $1.85 million. Xeris Biopharma reported solid first-quarter earnings, exceeding revenue estimates.
Xeris Biopharma Holdings Inc (XERS) Cash Flow
This article provides a detailed quarterly and annual cash flow statement for Xeris Biopharma Holdings Inc (XERS), covering operating, investing, and financing activities. It presents financial data from FY2017Q1 through FY2026Q1, allowing users to evaluate the company's financial soundness. The report also includes FAQs explaining key cash flow concepts and Xeris Biopharma's performance in these areas.
Xeris Biopharma Holdings Inc (XERS) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article from TradingKey provides an overview of Xeris Biopharma Holdings Inc (XERS) focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years. The page also presents current stock price information, market capitalization, and P/E ratio for XERS.
Xeris Biopharma Holdings, Inc. Revenue Breakdown – NASDAQ:XERS
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) generated a total revenue of $291.85 million USD last year. The primary segment contributing to this revenue was "Gvoke, Keveyis and Recorlev," which brought in $283.00 million USD. The vast majority of the company's revenue, $291.85 million USD, was sourced from the United States.
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Granahan Investment Management LLC
Granahan Investment Management LLC reduced its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 24.6% in the first quarter, selling 301,550 shares and retaining 921,854 shares valued at approximately $5.35 million. This divestment comes amidst mixed signals, with Weiss Ratings upgrading Xeris from "sell" to "hold" and MarketBeat data indicating a "Moderate Buy" consensus with an average price target of $10.80. Insider selling has also occurred, totaling 251,500 shares worth $1.85 million over the past three months.
XERS|Xeris Biopharma Holdings Inc|Price:8.320|Chg%:-0.090
Xeris Biopharma Holdings Inc (XERS) is currently trading at $8.32, down 1.07%. The company has healthy fundamentals, high growth potential, and is considered fairly valued within the Pharmaceuticals industry. Analysts have a "Buy" rating for XERS, with a target price of $11.29, suggesting a 34.19% upside.
Xeris Biopharma to report Q2 results, host conference call
Xeris Biopharma Holdings Inc. will release its second-quarter 2026 financial results before the U.S. market opens on August 6, 2026. The company will also host a conference call and webcast on the same day at 8:30 a.m. ET to discuss the results. This news brief was generated by Public Technologies using AI.
Xeris Biopharma Holdings Inc (XERS) Fundamental & Financial Data
This article provides fundamental and financial data for Xeris Biopharma Holdings Inc (XERS). It lists key financial metrics such as market capitalization, current price, dividend yield, PE ratio, and 52-week high/low. The article also includes recent news and earnings information for XERS.
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
Xeris Biopharma Holdings, Inc. announced that it will release its second quarter 2026 financial results on Thursday, August 6, 2026, before the U.S. financial markets open. Following the release, management will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results. The company, known for products like Recorlev, Gvoke, and Keveyis, focuses on developing and commercializing innovative therapies.
Press Release: Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
Xeris Biopharma Holdings, Inc. announced it will release its second-quarter 2026 financial results on August 6, 2026. The company will also host a conference call and webcast to discuss these results, providing stakeholders with an update on its performance. Investors can access the event details through the investor relations section of Xeris Biopharma's website.
Xeris Biopharma to report Q2 2026 results on Aug 6
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) will announce its second-quarter 2026 financial results on August 6, 2026, before market open. A conference call and webcast will follow at 8:30 a.m. ET to discuss the performance of its commercial products Recorlev, Gvoke, and Keveyis, and progress on its pipeline, including the Phase 3-ready XP-8121. Investors can access the webcast and replay via the company's Investor Relations website.
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
Xeris Biopharma Holdings, Inc. announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, before the U.S. financial markets open. Management will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss these results. The company, focused on innovative biopharmaceutical products, has three commercially available products and a development pipeline.
XERS5927663 Bond Coupon Profile — Rate & Payments
This article provides a coupon profile for the Xeris Biopharma Holdings, Inc. bond, XERS5927663. It details that the bond has a current coupon rate of 8.00% and its next interest payment is scheduled for January 15, 2027. The article offers an overview of the bond's interest payments and encourages users to unlock full data for more insights.
XERS5927663 Bond Risk Profile
This article provides an overview of the XERS5927663 bond from Xeris Biopharma Holdings, Inc., detailing its 8.0% coupon rate and a maturity date of July 15, 2028. It highlights key metrics for assessing credit risk, such as security level and issuer rating. The profile also mentions access to exclusive analyst ratings for bonds.
XERS5927663 Bond Profile — Key Metrics
This article provides a bond profile for XERS5927663, issued by Xeris Biopharma Holdings, Inc. Key details include an 8.0% coupon rate, a maturity date of July 15, 2028, and an outstanding amount of $10.57 million USD. The company, founded in 2005, is a biopharmaceutical firm developing products for conditions like severe hypoglycemia, primary periodic paralysis, and Cushing’s syndrome.
Xeris Biopharma (Nasdaq: XERS) ends 8% 2028 notes via cash and stock
Xeris Biopharma Holdings, Inc. has successfully eliminated all its 8.00% Convertible Senior Notes due 2028 through a combination of privately negotiated exchanges and conversions. Approximately $23 million of notes were exchanged for 5.0 million common shares and $23 million in cash, while another $10.5 million in notes was converted into 3.6 million common shares. As a result, no 2028 notes remain outstanding.
Emerald Mutual Fund Advisers Trust Acquires New Shares in Xeris Biopharma Holdings, Inc. $XERS
Emerald Mutual Fund Advisers Trust initiated a new position in Xeris Biopharma Holdings, Inc. by purchasing 207,543 shares valued at approximately $1.2 million during the first quarter. This comes amidst mixed analyst sentiment, with a recent downgrade from Weiss Ratings but a broader "Hold" consensus and an average price target of $10.80. The company recently exceeded analyst revenue expectations in its Q1 earnings, while some insiders have sold shares.
Xeris Biopharma CFO Steven Pieper sells $383,176 in company stock
Xeris Biopharma's CFO, Steven Pieper, sold 45,000 shares of company stock for approximately $383,176 in early July through a pre-arranged trading plan. This sale occurred after the stock delivered a 78% return over the past year, and InvestingPro data suggests the stock is currently overvalued. Despite the insider sale, Xeris Biopharma recently reported strong Q1 2026 financial results with a 38% revenue increase and positive EPS, along with news of a patent allowance for its Keveyis product and changes in corporate governance.
Price to earnings forward of Xeris Biopharma Holdings, Inc. – NASDAQ:XERS
The article focuses on the "Price to earnings forward" metric for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS). It appears to be a financial data page from TradingView, providing an overview of the company's financials for investors and analysts interested in its valuation.
Xeris Biopharma CFO Steven Pieper sells $383,176 in company stock By Investing.com
Steven Pieper, the CFO of Xeris Biopharma Holdings Inc. (NASDAQ:XERS), sold a total of 45,000 shares of company stock for approximately $383,176 in early July, under a pre-arranged trading plan. This sale follows a strong 78% return for the stock over the past year. After these transactions, Pieper directly owns 1,366,053 shares, and the stock is currently considered overvalued by InvestingPro.
Form 4 Xeris Pharmaceuticals Inc For: 7 July By Investing.com
This article reports on a Form 4 filing for Xeris Pharmaceuticals Inc. on July 7, 2026. Form 4s are SEC filings used to report changes in beneficial ownership of a company's stock by insiders. The article indicates that Xeris Pharmaceuticals Inc. (XERS) stock was up 6.93% at the time of publication.
Xeris Biopharma CFO Steven Pieper sells $383,176 in company stock By Investing.com
Xeris Biopharma Holdings Inc. CFO Steven Pieper sold 45,000 shares of company stock across two transactions in early July, totaling approximately $383,176. These sales were conducted under a pre-arranged trading plan, following a strong 78% return for the stock over the past year. Despite the insider sale, Pieper still holds a significant number of shares, and the company recently reported robust Q1 2026 financial results and strategic corporate governance changes.
Steven Pieper sells 17,400 shares for $147,900 — XERS
A recent SEC Form 144 filing indicates that Steven Pieper sold 17,400 shares of Xeris Biopharma Holdings, Inc. (XERS) common stock for a total of $147,900 on July 6, 2026. This transaction was executed under a 10b5-1 trading plan. The filing also notes prior issuer transactions for Pieper, including an open-market purchase in 2017 and Restricted Stock Units granted in 2017.
Xeris Biopharma (XERS) officer sells 45,000 shares under Rule 10b5-1 plan
Steven Pieper, an officer at Xeris Biopharma Holdings (XERS), sold 45,000 shares of common stock over two days, July 6-7, 2026, for a total of $383,176. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. After these transactions, Pieper directly holds 1,366,053 shares, which also includes shares acquired through an Employee Stock Purchase Plan.
